1. requiring mechanical ventilation (invasive or non-invasive) or high flow oxygen devices. 2. more than 7 days since symptoms (fever or cough). 3. participation in any other clinical trial of an experimental treatment for covid-19. 4. in the opinion of the clinical team, progression to death is imminent and inevitable within the next 24 hours, irrespective of the provision of treatments. 5. any incompatibility or allergy to the administration of human plasma. 6. stage 4 severe chronic kidney disease or requiring dialysis (i.e. egfr \<30).

1. requiring mechanical ventilation (invasive or non-invasive) or high flow oxygen devices. 2. more than 7 days since symptoms (fever or cough). 3. participation in any other clinical trial of an experimental treatment for covid-19. 4. in the opinion of the clinical team, progression to death is imminent and inevitable within the next 24 hours, irrespective of the provision of treatments. 5. any incompatibility or allergy to the administration of human plasma. 6. stage 4 severe chronic kidney disease or requiring dialysis (i.e. egfr \<30).

requiring mechanical ventilation (invasive or non-invasive) or high flow oxygen devices. more than 7 days since symptoms (fever or cough). participation in any other clinical trial of an experimental treatment for covid-19. in the opinion of the clinical team, progression to death is imminent and inevitable within the next 24 hours, irrespective of the provision of treatments. any incompatibility or allergy to the administration of human plasma. stage 4 severe chronic kidney disease or requiring dialysis (i.e. egfr <30).

requiring mechanical ventilation (invasive or non-invasive) or high flow oxygen devices. more than 7 days since symptoms (fever or cough). participation in any other clinical trial of an experimental treatment for covid-19. in the opinion of the clinical team, progression to death is imminent and inevitable within the next 24 hours, irrespective of the provision of treatments. any incompatibility or allergy to the administration of human plasma. stage 4 severe chronic kidney disease or requiring dialysis (i.e. egfr <30).

1. requiring mechanical ventilation (invasive or non-invasive) or high flow oxygen devices. 2. more than 7 days since symptoms (fever or cough). 3. participation in any other clinical trial of an experimental treatment for covid-19. 4. in the opinion of the clinical team, progression to death is imminent and inevitable within the next 24 hours, irrespective of the provision of treatments. 5. any incompatibility or allergy to the administration of human plasma. 6. stage 4 severe chronic kidney disease or requiring dialysis (i.e. egfr <30).

1. requiring mechanical ventilation (invasive or non-invasive) or high flow oxygen devices. 2. more than 7 days since symptoms (fever or cough). 3. participation in any other clinical trial of an experimental treatment for covid-19. 4. in the opinion of the clinical team, progression to death is imminent and inevitable within the next 24 hours, irrespective of the provision of treatments. 5. any incompatibility or allergy to the administration of human plasma. 6. stage 4 severe chronic kidney disease or requiring dialysis (i.e. egfr <30).

1. requiring mechanical ventilation (invasive or non-invasive) or high flow oxygen devices. 2. more than 12 days since symptoms (fever or cough). 3. participation in any other clinical trial of an experimental treatment for covid-19. 4. in the opinion of the clinical team, progression to death is imminent and inevitable within the next 24 hours, irrespective of the provision of treatments. 5. any incompatibility or allergy to the administration of human plasma. 6. stage 4 severe chronic kidney disease or requiring dialysis (i.e. egfr <30).

1. requiring mechanical ventilation (invasive or non-invasive) or high flow oxygen devices. 2. more than 12 days since symptoms (fever or cough). 3. participation in any other clinical trial of an experimental treatment for covid-19. 4. in the opinion of the clinical team, progression to death is imminent and inevitable within the next 24 hours, irrespective of the provision of treatments. 5. any incompatibility or allergy to the administration of human plasma. 6. stage 4 severe chronic kidney disease or requiring dialysis (i.e. egfr <30).